SBIR/STTR Research Award

Clean-Genome vaccines against biodefense agents

Award identifier efef1d4d9a4c087c75aaa4a1f07701005213eb73ec1915d19092cf69c9b46e2eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,000,000

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SCARAB GENOMICS LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
S4XQJDL7DN15
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Project description: We propose to develop a new vaccine delivery platform based on a non-pathogenic E. coli with specific safety features. Compared with other bacteria used for vaccines, the E. coli multi-deletion strain (MDS) has been extensively engineered, removing more than 40 large DNA segments totaling 15% of the genome. The deletions are designed to remove all mobile DNA, all genes that could have any role in pathogenicity, and other segments acquired by horizontal transfer, leaving a "clean", stable genome. This strain will deliver Shiga toxin vaccines directly into host cells. In this process, the vaccine vector gains direct access to cells of the submucosal immune system, where the vaccines molecules encoded in the strain are produced, provoking an immune response. The system is designed to deliver any or several vaccines, with a higher degree of safety than other bacterial systems. E. coli can be orally administered and is stable in storage. The genome can be readily resequenced using new chip technology, to give assurance of a completely defined system. On this platform, a vaccine against the Select Agent Shiga toxin will be built and tested. The toxin is a highly potent ribosome-inhibiting protein related to cholera toxin and ricin. It is produced by the enterohemorrhagic E. coli strain O157:H7 and other diarrheagenic strains. The toxin can cause Hemolytic Uremic Syndrome with fatal complications, by attacking microvascular epithelial cells in the kidney and central nervous system. Aims: 1) Construct MDS vaccine strains that contain a mutant Shiga toxin gene and are capable of invading human cells. 2) Evaluate candidate strains in the murine Shiga toxin protection model. Relevance to Public Health: There is no currently available vaccine or therapy to block the fatal kidney damage that Shiga toxin can cause. It presents a serious health threat to susceptible patients and even to healthy members of the general public if the toxin were to be used as a bioweapon. The clean-genome vaccine platform could provide safe protection from this and many other infectious diseases.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

25 SBIR/STTR records share this UEI (2004–2025). Reported award amounts total $25,829,458. Reported amounts are not federal obligations.

Phases: Phase II, Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.